| Today’s Big NewsDec 4, 2024 |
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now! 
|
|
| By Angus Liu AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the country. |
|
|
|
By Darren Incorvaia British immunology firm Scancell has found a repeat buyer for its monoclonal antibodies. Genmab has plucked another anti-glycan antibody from Scancell’s shelves to the tune of up to $630 million. The deal comes about two years after Genmab snagged its first antibody from Scancell for up to $624M, and it brings Genmab's potential tab to a hefty $1.27 billion. |
By Conor Hale The project will look to combine separate AI technologies currently under development by both the Mayo Clinic and Philips, which the company said could one day aid radiographers in completing difficult heart scans with less training. |
By Gabrielle Masson Mitsubishi Tanabe Pharma is offering Dewpoint Therapeutics up to $480 million biobucks in a new research pact centering around a preclinical amyotrophic lateral sclerosis program. |
|
The right funding at the right time is crucial for life sciences companies that want to fuel innovation and scale operations. Download this free whitepaper to drive innovation, expand operations and lead your organization to further success. 
|
|
By Kevin Dunleavy Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight. In the SURMOUNT-5 study, while participants taking Zepbound lost an average of 20.2% of their weight after 72 weeks, those on Wegovy lost 13.7% of their weight. |
By Fraiser Kansteiner Novo will invest 2.9 billion Danish kroner (roughly $409 million) to construct a new, 53,000-square-meter quality control laboratory in Hillerød, Denmark. Once completed, the new facility will act as a central hub for quality control operations in Denmark and consolidate existing locations at a single site. |
By Andrea Park BeiGene and the nonprofit CLL Society unveiled the “Test Before Treat” initiative Wednesday and will spotlight the campaign during the American Society of Hematology’s annual meeting, which kicks off in San Diego later this week. |
By Nick Paul Taylor Exact Sciences has enlisted Lil Jon, the poop emoji and a singing toilet for its latest Cologuard marketing push, remixing the rapper’s hit “Get Low” to encourage people to use its colon cancer screening test. |
By Nick Paul Taylor GSK has made another trip to China to build out its antibody-drug conjugate pipeline, returning with an option on a preclinical Duality Biologics candidate that could ultimately cost the Big Pharma $1 billion. |
By Kevin Dunleavy With AstraZeneca’s former international chief, Leon Wang, under investigation in China, the company has promoted an AZ veteran to fill the post. The British giant has appointed Iskra Reic, Ph.D., as its new international executive vice president. |
By Fraiser Kansteiner In a warning letter published Tuesday, the FDA scolded Applied Therapeutics on two counts related to its 47-patient study of govorestat in kids with classic galactosemia, specifically raising issues related to data deletion and a dosing error. The write-up was issued around the same time that the agency rejected govorestat's approval application. |
By Nick Paul Taylor Sumitomo Pharma’s Gemtesa marketing team is going again, re-upping its “Time To Go” campaign for a third year in a fresh push to get patients to talk to physicians about overactive bladder symptoms. |
By Fraiser Kansteiner Novavax is selling its 150,000-square-foot recombinant protein facility in Bohumil, Czech Republic, to Novo Nordisk for a total of $200 million. Under the deal, which is expected to close by Dec. 30, Novo will get its hands on the production site, support buildings and the plant’s entire existing workforce, which stands at around 300 people. |
By Andrea Park Not everyone will be able to hug their loved ones this holiday season—or throughout the year—but Klick Health, at least, is on a mission to change that for its own employees. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
The European orphan drug market presents a significant opportunity, with forecasts predicting substantial growth in the coming years. Early access programs (EAPs) have emerged as a critical strategy for successfully launching rare disease therapies in this complex and diverse market. Access this whitepaper to learn more. 
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
